Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share fell 44.64% over the past year to $5.68, which beat the estimate of $4.55.
Revenue of $2,775,000,000 decreased by 24.63% year over year, which beat the estimate of $2,610,000,000.
Guidance
Biogen raised the total revenue outlook for FY21 to $10.65 billion to $10.85 billion from prior guidance of $10.45 billion to $10.75 billion.
- Adjusted EPS outlook remains unchanged at $17.50 to $19.00, the mid-point being lower than the analyst consensus of $18.41.
Details Of The Call
Date: Jul 22, 2021
Time: 08:00 AM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1479841&tp_key=5ec330783d
Recent Stock Performance
52-week high: $468.55
Company's 52-week low was at $223.25
Price action over last quarter: Up 22.61%
Company Description
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
